Association of Gadolinium Based Magnetic Resonance Imaging Contrast Agents and Nephrogenic Systemic Fibrosis

Journal of Urology

Volumn 180, Issue 3, 2008, Pages 830-835

  Bhave, Gautam ^a   Lewis, Julia B ^a   Chang, Sam S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

gadolinium; kidney diseases; magnetic resonance imaging

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ACUTE KIDNEY INJURY; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; FIBROSIS; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INJURY; MAGNETIC RESONANCE ANGIOGRAPHY; MEDLINE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PRIORITY JOURNAL; RENOGRAPHY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; SKIN DISEASES;

EID: 48649110787     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.05.005     Document Type: Review

References (43)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000
2. Cowper S.E., Su L.D., Bhawan J., Robin H.S., and LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383
3. DeHoratius D.M., and Cowper S.E. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 19 (2006) 191
4. Grobner T., and Prischl F.C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72 (2007) 260
5. Swaminathan S., and Shah S.V. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18 (2007) 2636
6. Ting W.W., Stone M.S., Madison K.C., and Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 (2003) 903
7. Cassis T.B., Jackson J.M., Sonnier G.B., and Callen J.P. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 45 (2006) 56
8. Mackay-Wiggan J.M., Cohen D.J., Hardy M.A., Knobler E.H., and Grossman M.E. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48 (2003) 55
9. Swartz R.D., Crofford L.J., Phan S.H., Ike R.W., and Su L.D. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114 (2003) 563
10. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website], 2001-2007, and Cowper S.E. http://www.icnfdr.org Accessed October 24, 2007
11. Sadowski E.A., Bennett L.K., Chan M.R., Wentland A.L., Garrett A.L., Garrett R.W., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148
12. U.S. Food and Drug Administration: Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans (2006). http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200612HCP.htm Accessed October 24, 2007
13. Pharmacovigilance Working Party: Increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents (2007). http://www.ismrm.org/special/MHRA_Report.pdf Accessed November 18, 2007
14. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104
15. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., and Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586
16. Cheng S., Abramova L., Saab G., Turabelidze G., Patel P., Arduino M., et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 137
17. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359
18. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264
19. Wahba I.M., Simpson E.L., and White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 7 (2007) 2425
20. Collidge T.A., Thomson P.C., Mark P.B., Traynor J.P., Jardine A.G., Morris S.T., et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245 (2007) 168
21. Frost and Sullivan: North American MRI Contrast Media Market (2007), Frost and Sullivan, Vanderbilt University Walker Library, Nashville, TN. http://www.frost.com Published June 25, Accessed November 2, 2007
22. Marckmann P., Skov L., Rossen K., Heaf J.G., and Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174
23. Goyen M., Ruehm S.G., and Debatin J.F. MR-angiography: the role of contrast agents. Eur J Radiol 34 (2000) 247
24. U.S. Food and Drug Administration: Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (2007). http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm Accessed October 24, 2007
25. Idee J.M., Port M., Raynal I., Schaefer M., Le Greneur S., and Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563
26. Joffe P., Thomsen H.S., and Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 (1998) 491
27. Morcos S.K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 80 (2007) 73
28. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 (2007) 27
29. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21
30. Runge V.M., and Knopp M.V. Off-label use and reimbursement of contrast media in MR. J Magn Reson Imaging 10 (1999) 489
31. Hayes E. Bracco reports case of NSF with gadolinium contrast agent ProHance. Diagnostic Imaging (2007). http://www.dimag.com/showNews.jhtml?articleID=201802091 Accessed November 18, 2007
32. Goveia M., Chan B.P., and Patel P.R. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57 (2007) 725
33. Swaminathan S., Horn T.D., Pellowski D., Abul-Ezz S., Bornhorst J.A., Viswamitra S., et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357 (2007) 720
34. Okada S., Katagiri K., Kumazaki T., and Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 42 (2001) 339
35. Broome D.R., Cottrell A.C., and Kanal E. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". AJR Am J Roentgenol 189 (2007) W234
36. Kanal E., Barkovich A.J., Bell C., Borgstede J.P., Bradley Jr. W.G., Froelich J.W., et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188 (2007) 1447
37. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004) 1393
38. Barrett B.J., and Parfrey P.S. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 354 (2006) 379
39. Merten G.J., Burgess W.P., Gray L.V., Holleman J.H., Roush T.S., Kowalchuk G.J., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 (2004) 2328
40. Finn W.F. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 21 (2006) i2
41. Israel G.M., and Bosniak M.A. Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am 30 (2003) 499
42. Israel G.M., and Bosniak M.A. How I do it: evaluating renal masses. Radiology 236 (2005) 441
43. Maturen K.E., Nghiem H.V., Caoili E.M., Higgins E.G., Wolf Jr. J.S., and Wood Jr. D.P. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol 188 (2007) 563